NCT03678883 2026-04-039-ING-41 in Patients With Advanced CancersActuate Therapeutics Inc.Phase 2 Active not recruiting350 enrolled
NCT05704985 2025-05-29Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ TumorsDEKA BiosciencesPhase 1 Active not recruiting39 enrolled